← Back to Search

Monoclonal Antibodies

BMS-986403 for Chronic B-Cell Leukemia

Phase 1

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 2 years after bms-986403 infusion

Awards & highlights

Study Summary

This trial is testing a new drug for people with leukemia or lymphoma who have not responded to other treatments.

Eligible Conditions

Chronic B-Cell Leukemia
Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 2 years after bms-986403 infusion

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 2 years after bms-986403 infusion

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years after bms-986403 infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum-tolerated dose (MTD) based on the incidence of DLTs that occur during the DLT evaluation period

Number of participants with adverse events (AEs)

Number of participants with clinical laboratory abnormalities

+3 more

Secondary outcome measures

Complete remission rate (CRR)

Duration of complete remission (DOCR)

Duration of response (DOR)

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: BMS-986403 + Fludarabine + CyclophosphamideExperimental Treatment3 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Fludarabine

2012

Completed Phase 3

~1100

Cyclophosphamide

1995

Completed Phase 3

~3780

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,128,509 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper-limit of participants in this experiment?

"Affirmative. Information from clinicaltrials.gov denotes that this research is currently enrolling patients, with the trial having been first uploaded on September 14th 2022 and last modified on September 29th 2022. The medical study requires 65 volunteers across 18 sites to meet its recruitment goals."

Answered by AI

Are there still positions available for volunteers in this experiment?

"Clinicaltrials.gov reveals that this experiment is presently recruiting participants, with the study first posted on September 14th and most recently amended on September 29th."

Answered by AI

What are the potential risks associated with administering BMS-986403 to patients?

"Since BMS-986403 is currently in its first phase of clinical trials, there are limited data regarding the drug's efficacy and safety. Subsequently, our team graded this medication a 1 on our scale from 1 to 3."

Answered by AI

Are there any Canadian research centers which are currently conducting this clinical trial?

"18 different medical centres are currently involved in the clinical trial, including The Ohio State University Wexner Medical Centre James Cancer Hospital in Columbus, Massachusetts General Hospital-Medical Oncology in Boston and a Local Institution based out of Seattle. Additionally, there is an assortment of other locations participating as well."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

2022. "A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05244070.